Opaleye Management Inc. - Apr 29, 2022 Form 4 Insider Report for Tracon Pharmaceuticals, Inc. (TCON)

Role
10%+ Owner
Signature
Opaleye Management Inc., By: /s/ James Silverman, President
Stock symbol
TCON
Transactions as of
Apr 29, 2022
Transactions value $
$14,058
Form type
4
Date filed
4/29/2022, 06:27 PM
Previous filing
Apr 25, 2022
Next filing
May 10, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TCON Common Stock, par value $0.001 per share Purchase $12.1K +6.1K +0.21% $1.98 2.93M Apr 22, 2022 By Opaleye, L.P. F1, F3
transaction TCON Common Stock, par value $0.001 per share Purchase $1.98K +1K +0.3% $1.98 336K Apr 22, 2022 By Managed Account F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding TCON Prefunded Warrants 1.89M Apr 29, 2022 Common Stock 1.89M $0.01 By Opaleye,L.P. F1, F4
holding TCON Prefunded Warrants 1.36M Apr 29, 2022 Common Stock 1.36M $0.01 By Opaleye,L.P. F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents securities owned directly by Opaleye, L.P. (the "Fund"). As the investment manager of the Fund, Opaleye Management Inc. may be deemed to beneficially own the securities owned directly by the Fund.
F2 Securities owned by a separately managed account (the "Managed Account"). As the portfolio manager of the Managed Account, Opaleye may be deemed to beneficially own the securities owned directly by the Managed Account.
F3 The common stock was purchased by the reporting person in open market transactions on the transaction date, with a purchase price of $1.98. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased.
F4 The warrants may not be exercised to the extent that such exercise would cause the reporting person and its affiliates to beneficially own more than 9.99% of the issuers then outstanding shares.